source
- Michael J. Fox Foundation backs Ariadne Bio's non-hallucinogenic psychedelic for Parkinson'sAriadne Bio, a new biotech focused on Parkinson's disease, has received backing from the Michael J. Fox Foundation. The partnership centers on a non‑hallucinogenic psychedelic candidate that the fo…
- Bristol Myers ends $100M Phase 1 cancer ADC programBristol Myers Squibb announced it has discontinued development of its Phase 1 antibody-drug conjugate candidate BMS-986497/ORM-6151. The decision follows a review of early clinical data, leading t…